% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

  • ron.wallach ron.wallach Jun 28, 2013 2:48 PM Flag

    Dendreon (DNDN) introduced the first proven immunotherapy, Provenge for metastatic, minimally symptomatic, castrate-resistant prostate cancer, in the United States after FDA approval in 2010. After a spike in the stock price to over $50 per share



    Sentiment: Buy

    This topic is deleted.
0.130.00(0.00%)Nov 18 4:00 PMEST